OrthoPediatrics Corp reports results for the quarter ended September 30 - Earnings Summary

What happened

OrthoPediatrics Corp reported an adjusted quarterly loss of 28 cents per share, wider than the 21 cents expected by analysts, while revenue rose 18.6% to $72.66 million, beating the $68.50 million estimate. The company posted a quarterly loss of $5.93 million.

Confirmed

Global impact / market context

The wider adjusted loss shows costs or spending grew faster than sales despite strong revenue, which means the company was less efficient at turning sales into profit. That gap could pressure the share price even as analyst ratings stay at buy.

Analyst inference

Shares had risen 7.9% this quarter and 35.2% this year, so expectations were high. The analyst median 12-month price target is $25.00, about 3.9% above the last closing price of $24.02, suggesting limited expected upside remaining.

Analyst inference

What to watch

1. The current average analyst rating is buy, with 7 strong buy or buy, 1 hold and no sell or strong sell recommendations, which means most covered analysts still expect the stock to perform well. Confirmed
2. Revenue beat estimates while the adjusted loss was wider than expected, so watch whether future quarters show profit per sale improving as higher sales spread fixed costs. Analyst inference
3. Watch whether the company slows spending or raises prices to narrow its adjusted loss, since that path would show if the revenue growth can translate into smaller losses. Proposed

Evidence

• Original source link unavailable